cbdMD, Inc. (NYSE: YCBD)

cbdMD, Inc. is a consumer wellness company specializing in the development, manufacturing, and marketing of supplement brands centered on natural compounds, primarily hemp-derived cannabinoids. The company focuses on creating products that address key wellness needs, including sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. Its portfolio combines scientific research with high manufacturing standards to produce consistent, safe, and regulatory-compliant products. cbdMD operates in the rapidly evolving hemp and cannabinoid-based supplement industry, positioning itself as a leader in innovation and quality.

The company generates revenue through the sale of a diverse range of products, including broad-spectrum and full-spectrum CBD formulations, hemp-derived Delta-9 THC products (where legally permitted), and functional supplements. Its offerings span oils, gummies, capsules, soft-gels, topicals, pet wellness products, and ready-to-drink beverages. Sales are driven through a multi-channel distribution network, comprising direct-to-consumer e-commerce platforms, online marketplaces, wholesale distribution to national and regional retailers, specialty health and pet channels, and international markets. In fiscal 2025, approximately 77% of revenue came from e-commerce, while wholesale and international distribution contributed the remainder.

The company operates through the following segments:

• cbdMD: This segment represents the flagship brand, offering a comprehensive line of hemp-derived cannabinoid products, including oils, gummies, capsules, soft-gels, topicals, and compliant Delta-9 THC formulations. The brand targets human wellness, emphasizing scientific backing, safety, and efficacy to meet consumer demand for high-quality supplements.

• Paw CBD: This segment focuses on pet wellness, providing hemp-derived cannabinoid products such as tinctures, chews, and topicals for dogs and cats. The brand prioritizes safety and quality, catering to pet owners seeking natural solutions for animal health and mobility.

• ATRX: This segment explores emerging and novel non-cannabinoid functional ingredients, including functional mushrooms and performance-driven nutraceuticals. ATRX supports the company’s expansion into nootropic and synergistic ingredient combinations, targeting cognitive and physical performance.

• Herbal Oasis (Oasis): This segment features a premium hemp-derived THC-infused social seltzer, blending cannabinoids and nootropic mushrooms to create a fast-acting, functional beverage. The brand is distributed through beverage and alcohol distributors, as well as retail chains, and is positioned for growth in the ready-to-drink market.

cbdMD operates in a highly competitive and fragmented dietary supplement market, where it distinguishes itself through a focus on hemp-derived cannabinoids and emerging functional ingredients. The U. S. cannabinoid market includes over 2,000 brands, with no single dominant player, creating opportunities for differentiation. The company competes with both public and private companies across e-commerce, wholesale, and brick-and-mortar retail channels. Key competitive advantages include its commitment to clinical research, peer-reviewed studies, and proprietary formulations that substantiate product efficacy and safety. Additionally, cbdMD’s multi-brand portfolio, regulatory compliance, and hybrid manufacturing model enable it to adapt quickly to market trends and regulatory changes. However, the company faces challenges from synthetic cannabinoids and evolving federal regulations, which could impact its product offerings and revenue streams.

The company serves a broad and diverse customer base, including individual consumers, pet owners, retailers, and distributors. Its direct-to-consumer business is driven by e-commerce platforms such as its own websites, while wholesale partners include national and regional retailers like Sprouts, Total Wine, Winn-Dixie, Piggly Wiggly, and GNC. The Oasis brand is distributed through beverage and alcohol distributors, as well as grocery and convenience store chains. Internationally, cbdMD partners with local wholesalers and distributors to navigate regulatory requirements in markets such as Central and South America, the European Union, and the United Kingdom.